By Laura Smith - University of New Mexico/Talk Radio News Service
Health officials announced today that there are about 30 million doses of the H1N1 vaccine available for states to order.
The annoucement was coupled with good news for people who health officials believe are at serious risk of contracting the virus. Anthony Facui, Director of the National Institute of Allergy and Infectious Diseases, said that results from a series of vaccine tests done on groups such as pregnant women were encouraging.
“The data show that nearly all the pregnant women who received a single 15 microgram dose have a robust immune response that is likely predictive of protection,” Facui said.
He added that children between six months and nine-years-old who receive a 15 microgram dose of the vaccine had a “less robust immune response” and would most likely need a second dose of vaccine.
Not all of the news surrounding H1NI is positive, however. Anne Schuchat, Director of the National Center for Immunization and Respiratory Diseases at the Center for Disease Control and Prevention, said that the virus has spread to all but two states in the U.S. Schuchat was hopeful that, as the number of hospitalizations and deaths as a result of the virus continue to increase, so will the medical response nationwide.
“We expect more vaccine doses to become available and eventually shipped out to the states for use,” she said.
A full report on the study was posted today on flu.gov.
New H1N1 Vaccine Study Shows Good News For Pregnant Women
Health officials announced today that there are about 30 million doses of the H1N1 vaccine available for states to order.
The annoucement was coupled with good news for people who health officials believe are at serious risk of contracting the virus. Anthony Facui, Director of the National Institute of Allergy and Infectious Diseases, said that results from a series of vaccine tests done on groups such as pregnant women were encouraging.
“The data show that nearly all the pregnant women who received a single 15 microgram dose have a robust immune response that is likely predictive of protection,” Facui said.
He added that children between six months and nine-years-old who receive a 15 microgram dose of the vaccine had a “less robust immune response” and would most likely need a second dose of vaccine.
Not all of the news surrounding H1NI is positive, however. Anne Schuchat, Director of the National Center for Immunization and Respiratory Diseases at the Center for Disease Control and Prevention, said that the virus has spread to all but two states in the U.S. Schuchat was hopeful that, as the number of hospitalizations and deaths as a result of the virus continue to increase, so will the medical response nationwide.
“We expect more vaccine doses to become available and eventually shipped out to the states for use,” she said.
A full report on the study was posted today on flu.gov.